PTC Therapeutics filings document a Delaware biopharmaceutical company with common stock listed on the Nasdaq Global Select Market under PTCT. Its Form 8-K reports cover quarterly and annual financial results, Regulation FD disclosures, product and pipeline updates, FDA-related communications, and board or compensation matters.
Proxy materials describe annual meeting governance, director elections, executive compensation, equity awards and related shareholder matters. The filing record also includes disclosures tied to rare-disease programs such as Sephience™ (sepiapterin), votoplam and Translarna™ (ataluren), along with the company’s capital structure and public-company reporting obligations.
PTC Therapeutics, Inc. chief executive officer Matthew B. Klein reported an automatic sale of 10,292 shares of common stock on 2026-08-04 at $68.57 per share. The sale was executed under an irrevocable sell-to-cover election pursuant to a Rule 10b5-1 trading plan to satisfy tax withholding obligations upon vesting of 25,000 RSUs from an August 1, 2025 grant of 75,000 RSUs. Following this transaction, Klein directly holds 383,868 shares of common stock, which include 162 shares acquired through the employee stock purchase plan for the period ended 2026-06-30.
Matthew Klein has filed to sell common stock of PTCT under Rule 144. The filing covers 10,292 shares of common stock to be sold through Fidelity Brokerage Services LLC on or after August 4, 2026 on NASDAQ, with an aggregate market value of $705,754.35. These shares arose from restricted stock vesting granted by the issuer as compensation on August 3, 2026. The filing also reports that on May 14, 2026, Klein previously sold 12,572 shares of common stock for an aggregate market value of $917,129.43.
PTC Therapeutics, Inc. director Hege Elisabeth Sollie-Zetlmayer received multiple equity awards on July 28, 2026. Grants included 4,000 restricted stock units vesting in three equal annual installments from July 28, 2027, and 2,000 restricted stock units vesting on January 2, 2027. She was also granted stock options for 3,475 and 1,738 shares of common stock at an exercise price of $75.39 per share, vesting over 36 and six equal monthly installments respectively, with both option grants expiring on July 27, 2036.
PTC Therapeutics, Inc. director Hege Elisabeth Sollie-Zetlmayer reports beneficial ownership of 46,526 shares of common stock held directly, including multiple unvested RSU awards. She also holds several stock options over common stock, three of which are currently exercisable for 14,000, 33,250 and 17,875 shares at exercise prices of $51.96, $66.49 and $38.10, respectively, with additional option grants vesting over four years on specified schedules.
PTC Therapeutics, Inc. reported strong Q2 2026 results, with total revenues of $360.5 million, up from $178.9 million a year earlier. Growth was driven by net product revenue of $238.8 million and collaboration and license revenue of $50.6 million, including a $50.0 million milestone from Novartis for Huntington’s disease candidate votoplam. Royalty revenue contributed $71.1 million. Operating income reached $149.0 million and net income attributable to common stockholders was $83.5 million, or diluted EPS of $0.92, versus a prior-year loss.
PTC ended June 30, 2026 with $1.05 billion in cash and cash equivalents and $1.18 billion in marketable securities, against roughly $591 million of debt and a $2.32 billion liability for sale of future Evrysdi royalties, leaving stockholders’ deficit at $165.4 million. In June it issued $550.0 million of 0% convertible senior notes due 2031 and repurchased $222.0 million of its 1.50% notes due 2026, leaving $55.5 million outstanding. Operationally, Sephience for PKU is now approved in the U.S., EU, Japan, Brazil and additional geographies; Novartis commenced a global Phase 3 votoplam trial; PTC initiated a Phase 1 study of PTC612, plans a Phase 2a study of PTC844 and expects to start the PROVE-FA study of vatiquinone in Q3 2026. The company expects product cash flows, Novartis milestones and existing liquidity to fund operations for at least 12 months.
PTC Therapeutics reported strong second-quarter 2026 results, with total revenue of $361 million, including $239 million of product revenue. Sephience generated $151 million of Q2 2026 revenue and had 1,647 patients on commercial therapy worldwide as of June 30, 2026. Total net product and royalty revenue was $309.9 million versus $175.9 million a year earlier, and net income attributable to common stockholders was $83.5 million, compared with a $64.8 million loss in Q2 2025; diluted EPS was $0.92.
The company raised full-year 2026 guidance, targeting total revenue of $1.18 to $1.28 billion and product revenue of $850 to $950 million. Projected 2026 GAAP R&D and SG&A expense is $775 to $815 million, with non-GAAP expected at $680 to $720 million. Cash and marketable securities were about $2.2 billion as of June 30, 2026, with total debt of $590.97 million and a $2.32 billion liability for sale of future royalties.
Pipeline updates included positive 24‑month PIVOT‑HD data for votoplam showing 52% dose‑dependent disease slowing on the cUHDRS at the 10 mg dose in Stage 2 participants, and a Novartis-funded Phase 3 INVEST‑HD trial (~770 patients) that triggered a $50 million milestone payment. PTC named PTC303 as its next MSH3 splicing candidate, initiated Phase 1 for PTC612 and plans a Phase 2a study of PTC844 in Q3 2026. The company also appointed Hege Sollie‑Zetlmayer to its board as a Class III director, granting equity awards under its director compensation policy.
PTC Therapeutics' chief financial officer Pierre Gravier automatically sold 3,494 shares of common stock on July 14, 2026 at $80.35 per share pursuant to an irrevocable sell-to-cover election to satisfy tax withholding obligations tied to the vesting of 6,500 RSUs from a 26,000 RSU grant. After this transaction, he directly holds 83,986 shares, including 162 shares acquired through the employee stock purchase plan.
PTC Therapeutics director Mary L. Smith exercised stock options for 15,834 shares of common stock at an exercise price of $42.95 per share and sold 15,834 shares in open-market transactions at $90.00 per share on July 9, 2026. The sales were effected pursuant to a written Rule 10b5-1 trading plan adopted on November 11, 2025. Following these transactions, she holds 21,813 shares of PTC Therapeutics common stock directly.
Neil Gregory Almstead, Chief Technical Ops Officer of PTC Therapeutics, exercised stock options to acquire 2,464 common shares at $46.54 and on the same day sold 2,464 shares at a weighted average of $90.25 per share under a pre-arranged Rule 10b5-1 plan. Following these transactions, he holds 60,299 shares directly, 2,899 shares indirectly through his spouse, and 45,036 stock options granted January 3, 2025 that vest over four years and expire January 2, 2035.